{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:12:22Z","timestamp":1769605942338,"version":"3.49.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,12,4]],"date-time":"2017-12-04T00:00:00Z","timestamp":1512345600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s12032-017-1065-4","type":"journal-article","created":{"date-parts":[[2017,12,4]],"date-time":"2017-12-04T12:25:21Z","timestamp":1512390321000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies: validation of the Khorana Risk Score"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1585-6410","authenticated-orcid":false,"given":"Joanna","family":"Rupa-Matysek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidia","family":"Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Ka\u017amierczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Bara\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mieczys\u0142aw","family":"Komarnicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,4]]},"reference":[{"issue":"7","key":"1065_CR1","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1055\/s-0035-1564040","volume":"41","author":"A Falanga","year":"2015","unstructured":"Falanga A, Schieppati F, Russo D. Cancer tissue procoagulant mechanisms and the hypercoagulable state of patients with cancer. Semin Thromb Hemost. 2015;41(7):756\u201364. https:\/\/doi.org\/10.1055\/s-0035-1564040 .","journal-title":"Semin Thromb Hemost"},{"issue":"10","key":"1065_CR2","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","volume":"122","author":"JF Timp","year":"2013","unstructured":"Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122(10):1712\u201323. https:\/\/doi.org\/10.1182\/blood-2013-04-460121 .","journal-title":"Blood"},{"issue":"12","key":"1065_CR3","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1182\/blood-2013-04-460147","volume":"122","author":"I Pabinger","year":"2013","unstructured":"Pabinger I, Thaler J, Ay C. Biomarkers for prediction of venous thromboembolism in cancer. Blood. 2013;122(12):2011\u20138. https:\/\/doi.org\/10.1182\/blood-2013-04-460147 .","journal-title":"Blood"},{"issue":"2","key":"1065_CR4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1160\/TH16-08-0615","volume":"117","author":"C Ay","year":"2017","unstructured":"Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: burden, mechanisms, and management. Thromb Haemost. 2017;117(2):219\u201330. https:\/\/doi.org\/10.1160\/TH16-08-0615 .","journal-title":"Thromb Haemost"},{"issue":"10","key":"1065_CR5","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","volume":"111","author":"AA Khorana","year":"2008","unstructured":"Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902\u20137. https:\/\/doi.org\/10.1182\/blood-2007-10-116327 .","journal-title":"Blood"},{"issue":"24","key":"1065_CR6","doi-asserted-by":"publisher","first-page":"5377","DOI":"10.1182\/blood-2010-02-270116","volume":"116","author":"C Ay","year":"2010","unstructured":"Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24):5377\u201382. https:\/\/doi.org\/10.1182\/blood-2010-02-270116 .","journal-title":"Blood"},{"issue":"2","key":"1065_CR7","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/sj.leu.2405062","volume":"22","author":"A Palumbo","year":"2008","unstructured":"Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22(2):414\u201323. https:\/\/doi.org\/10.1038\/sj.leu.2405062 .","journal-title":"Leukemia"},{"issue":"2","key":"1065_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1160\/th12-01-0010","volume":"108","author":"YB Yu","year":"2012","unstructured":"Yu YB, Gau JP, Liu CY, Yang MH, Chiang SC, Hsu HC, et al. A nation-wide analysis of venous thromboembolism in 497,180 cancer patients with the development and validation of a risk-stratification scoring system. Thromb Haemost. 2012;108(2):225\u201335. https:\/\/doi.org\/10.1160\/th12-01-0010 .","journal-title":"Thromb Haemost"},{"issue":"20","key":"1065_CR9","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.1158\/1078-0432.ccr-14-0574","volume":"20","author":"OA O\u2019Connor","year":"2014","unstructured":"O\u2019Connor OA, Tobinai K. Putting the clinical and biological heterogeneity of non-hodgkin lymphoma into context. Clin Cancer Res. 2014;20(20):5173\u201381. https:\/\/doi.org\/10.1158\/1078-0432.ccr-14-0574 .","journal-title":"Clin Cancer Res"},{"key":"1065_CR10","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008.","edition":"4"},{"issue":"14","key":"1065_CR11","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"T Okamura","year":"1993","unstructured":"Okamura T. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987\u201394.","journal-title":"N Engl J Med"},{"issue":"27","key":"1065_CR12","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800 .","journal-title":"J Clin Oncol"},{"issue":"2 Suppl 5","key":"1065_CR13","first-page":"38","volume":"19","author":"V Bonfante","year":"1992","unstructured":"Bonfante V, Santoro A, Viviani S, Valagussa P, Bonadonna G. ABVD in the treatment of Hodgkin\u2019s disease. Semin Oncol. 1992;19(2 Suppl 5):38\u201344.","journal-title":"Semin Oncol"},{"issue":"5","key":"1065_CR14","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/s1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379\u201391. https:\/\/doi.org\/10.1016\/s1470-2045(06)70664-7 .","journal-title":"Lancet Oncol"},{"issue":"26","key":"1065_CR15","doi-asserted-by":"publisher","first-page":"5322","DOI":"10.1182\/blood-2010-01-258624","volume":"115","author":"V Caruso","year":"2010","unstructured":"Caruso V, Di Castelnuovo A, Meschengieser S, Lazzari MA, de Gaetano G, Storti S, et al. Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events. Blood. 2010;115(26):5322\u20138. https:\/\/doi.org\/10.1182\/blood-2010-01-258624 .","journal-title":"Blood"},{"issue":"8","key":"1065_CR16","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1515\/cclm-2014-1010","volume":"53","author":"M Franchini","year":"2015","unstructured":"Franchini M. Thromboembolic risk in hematological malignancies. Clin Chem Lab Med. 2015;53(8):1139\u201347. https:\/\/doi.org\/10.1515\/cclm-2014-1010 .","journal-title":"Clin Chem Lab Med"},{"issue":"6","key":"1065_CR17","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1080\/10428190600560991","volume":"47","author":"RS Komrokji","year":"2006","unstructured":"Komrokji RS, Uppal NP, Khorana AA, Lyman GH, Kaplan KL, Fisher RI, et al. Venous thromboembolism in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2006;47(6):1029\u201333. https:\/\/doi.org\/10.1080\/10428190600560991 .","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"1065_CR18","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1600-0609.1995.tb00214.x","volume":"54","author":"H Ottinger","year":"1995","unstructured":"Ottinger H, Belka C, Kozole G, Engelhard M, Meusers P, Paar D, et al. Deep venous thrombosis and pulmonary artery embolism in high-grade non Hodgkin\u2019s lymphoma: incidence, causes and prognostic relevance. Eur J Haematol. 1995;54(3):186\u201394.","journal-title":"Eur J Haematol"},{"issue":"10","key":"1065_CR19","doi-asserted-by":"publisher","first-page":"4833","DOI":"10.1182\/blood-2008-02-137760","volume":"111","author":"CJM Doggen","year":"2008","unstructured":"Doggen CJM. Thromboprophylaxis in cancer outpatients. Blood. 2008;111(10):4833. https:\/\/doi.org\/10.1182\/blood-2008-02-137760 .","journal-title":"Blood."},{"issue":"6","key":"1065_CR20","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1160\/TH12-04-0241","volume":"108","author":"J Thaler","year":"2012","unstructured":"Thaler J, Ay C, Pabinger I. Venous thromboembolism in cancer patients\u2014risk scores and recent randomised controlled trials. Thromb Haemost. 2012;108(6):1042\u20138. https:\/\/doi.org\/10.1160\/TH12-04-0241 .","journal-title":"Thromb Haemost"},{"issue":"6","key":"1065_CR21","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1093\/annonc\/mdr524","volume":"23","author":"M Mandala","year":"2012","unstructured":"Mandala M, Clerici M, Corradino I, Vitalini C, Colombini S, Torri V, et al. Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the \u2018SENDO experience\u2019. Ann Oncol. 2012;23(6):1416\u201321. https:\/\/doi.org\/10.1093\/annonc\/mdr524 .","journal-title":"Ann Oncol"},{"issue":"25","key":"1065_CR22","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1200\/jco.2011.35.5669","volume":"29","author":"RA Moore","year":"2011","unstructured":"Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011;29(25):3466\u201373. https:\/\/doi.org\/10.1200\/jco.2011.35.5669 .","journal-title":"J Clin Oncol"},{"issue":"10","key":"1065_CR23","first-page":"266","volume":"2","author":"SH Lim","year":"2015","unstructured":"Lim SH, Woo SY, Kim S, Ko YH, Kim WS, Kim SJ. Cross-sectional study of patients with Diffuse Large B-cell lymphoma: assessing the effect of host status, tumor burden and inflammatory activity on venous thromboembolism. Cancer Res Treat. 2015;2(10):266.","journal-title":"Cancer Res Treat"},{"key":"1065_CR24","doi-asserted-by":"publisher","DOI":"10.1160\/TH16-11-0895","author":"RM Santi","year":"2017","unstructured":"Santi RM, Ceccarelli M, Bernocco E, Monagheddu C, Evangelista A, Valeri F, et al. Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL). Thromb Haemost. 2017;. https:\/\/doi.org\/10.1160\/TH16-11-0895 .","journal-title":"Thromb Haemost"},{"issue":"2","key":"1065_CR25","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/jth.13205","volume":"14","author":"M Pepin","year":"2016","unstructured":"Pepin M, Kleinjan A, Hajage D, Buller HR, Di Nisio M, Kamphuisen PW, et al. ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer. J Thromb Haemost. 2016;14(2):306\u201315. https:\/\/doi.org\/10.1111\/jth.13205 .","journal-title":"J Thromb Haemost"},{"issue":"7","key":"1065_CR26","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa1108898","volume":"366","author":"G Agnelli","year":"2012","unstructured":"Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366(7):601\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1108898 .","journal-title":"N Engl J Med"},{"issue":"21","key":"1065_CR27","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/blood.V118.21.206.206","volume":"118","author":"D George","year":"2011","unstructured":"George D, Agnelli G, Fisher W, Kakkar A, Lassen MR, Mismetti P, et al. Venous thromboembolism (VTE) prevention with semuloparin in cancer patients initiating chemotherapy: benefit-risk assessment by VTE risk in SAVE-ONCO. Blood. 2011;118(21):206.","journal-title":"Blood"},{"issue":"5","key":"1065_CR28","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/jco.2015.64.0268","volume":"34","author":"F Macbeth","year":"2016","unstructured":"Macbeth F, Noble S, Evans J, Ahmed S, Cohen D, Hood K, et al. Randomized Phase III Trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC Trial. J Clin Oncol. 2016;34(5):488\u201394. https:\/\/doi.org\/10.1200\/jco.2015.64.0268 .","journal-title":"J Clin Oncol"},{"issue":"3","key":"1065_CR29","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/jth.13594","volume":"15","author":"S Noble","year":"2017","unstructured":"Noble S, Alikhan R, Robbins A, Macbeth F, Hood K. Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer: comment. J Thromb Haemost. 2017;15(3):590\u20131. https:\/\/doi.org\/10.1111\/jth.13594 .","journal-title":"J Thromb Haemost"},{"issue":"5","key":"1065_CR30","first-page":"442","volume":"83","author":"D Sgarabotto","year":"1998","unstructured":"Sgarabotto D, Prandoni P, Stefani PM, Scano F, Vianello F, Sartori R, et al. Prevalence and patterns of symptomatic thromboembolism in oncohematology. Haematologica. 1998;83(5):442\u20136.","journal-title":"Haematologica"},{"issue":"8","key":"1065_CR31","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/sj.bjc.6602504","volume":"92","author":"M Mohren","year":"2005","unstructured":"Mohren M, Markmann I, Jentsch-Ullrich K, Koenigsmann M, Lutze G, Franke A. Increased risk of thromboembolism in patients with malignant lymphoma: a single-centre analysis. Br J Cancer. 2005;92(8):1349\u201351.","journal-title":"Br J Cancer"},{"issue":"3","key":"1065_CR32","first-page":"14","volume":"130","author":"LC Park","year":"2012","unstructured":"Park LC, Woo SY, Kim S, Jeon H, Ko YH, Kim SJ, et al. Incidence, risk factors and clinical features of venous thromboembolism in newly diagnosed lymphoma patients: results from a prospective cohort study with Asian population. Thromb Res. 2012;130(3):14.","journal-title":"Thromb Res"},{"issue":"9","key":"1065_CR33","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1111\/jth.13378","volume":"14","author":"AS Mansfield","year":"2016","unstructured":"Mansfield AS, Tafur AJ, Wang CE, Kourelis TV, Wysokinska EM, Yang P. Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer. J Thromb Haemost. 2016;14(9):1773\u20138. https:\/\/doi.org\/10.1111\/jth.13378 .","journal-title":"J Thromb Haemost"},{"key":"1065_CR34","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.thromres.2016.12.013","volume":"150","author":"N Es van","year":"2017","unstructured":"van Es N, Franke VF, Middeldorp S, Wilmink JW, Buller HR. The Khorana score for the prediction of venous thromboembolism in patients with pancreatic cancer. Thromb Res. 2017;150:30\u20132. https:\/\/doi.org\/10.1016\/j.thromres.2016.12.013 .","journal-title":"Thromb Res"},{"issue":"10","key":"1065_CR35","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/ajh.24466","volume":"91","author":"D Antic","year":"2016","unstructured":"Antic D, Milic N, Nikolovski S, Todorovic M, Bila J, Djurdjevic P, et al. Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients. Am J Hematol. 2016;91(10):1014\u20139. https:\/\/doi.org\/10.1002\/ajh.24466 .","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"1065_CR36","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1016\/s0049-3848(16)30108-6","volume":"140","author":"D Imberti","year":"2016","unstructured":"Imberti D, Benedetti R. Primary prophylaxis of VTE in cancer outpatients. Thromb Res. 2016;140(Suppl 1):S103\u20138. https:\/\/doi.org\/10.1016\/s0049-3848(16)30108-6 .","journal-title":"Thromb Res"},{"issue":"1","key":"1065_CR37","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11239-015-1313-4","volume":"41","author":"AA Khorana","year":"2016","unstructured":"Khorana AA, Carrier M, Garcia DA, Lee AY. Guidance for the prevention and treatment of cancer-associated venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):81\u201391. https:\/\/doi.org\/10.1007\/s11239-015-1313-4 .","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"1065_CR38","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","volume":"5","author":"AA Khorana","year":"2007","unstructured":"Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632\u20134. https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02374.x .","journal-title":"J Thromb Haemost"},{"issue":"7","key":"1065_CR39","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1634\/theoncologist.2015-0361","volume":"21","author":"NM Kuderer","year":"2016","unstructured":"Kuderer NM, Culakova E, Lyman GH, Francis C, Falanga A, Khorana AA. A validated risk score for venous thromboembolism is predictive of cancer progression and mortality. Oncologist. 2016;21(7):861\u20137. https:\/\/doi.org\/10.1634\/theoncologist.2015-0361 .","journal-title":"Oncologist"},{"issue":"11","key":"1065_CR40","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1002\/cncr.29298","volume":"121","author":"DP Sohal","year":"2015","unstructured":"Sohal DP, Shrotriya S, Glass KT, Pelley RJ, McNamara MJ, Estfan B, et al. Predicting early mortality in resectable pancreatic adenocarcinoma: a cohort study. Cancer. 2015;121(11):1779\u201384. https:\/\/doi.org\/10.1002\/cncr.29298 .","journal-title":"Cancer"},{"issue":"Suppl 2","key":"1065_CR41","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/s0049-3848(14)50004-7","volume":"133","author":"A Mahajan","year":"2014","unstructured":"Mahajan A, Wun T, Chew H, White RH. Lymphoma and venous thromboembolism: influence on mortality. Thromb Res. 2014;133(Suppl 2):S23\u20138. https:\/\/doi.org\/10.1016\/s0049-3848(14)50004-7 .","journal-title":"Thromb Res"},{"issue":"5","key":"1065_CR42","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s11739-013-0985-z","volume":"9","author":"G Agnelli","year":"2014","unstructured":"Agnelli G, Verso M, Mandala M, Gallus S, Cimminiello C, Apolone G, et al. A prospective study on survival in cancer patients with and without venous thromboembolism. Intern Emerg Med. 2014;9(5):559\u201367. https:\/\/doi.org\/10.1007\/s11739-013-0985-z .","journal-title":"Intern Emerg Med"},{"issue":"25","key":"1065_CR43","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","volume":"343","author":"HT Sorensen","year":"2000","unstructured":"Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343(25):1846\u201350. https:\/\/doi.org\/10.1056\/NEJM200012213432504 .","journal-title":"N Engl J Med"},{"key":"1065_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2321","author":"J Rupa-Matysek","year":"2016","unstructured":"Rupa-Matysek J, Gil L, Kroll-Balcerzak R, Baranska M, Komarnicki M. Mean platelet volume as a predictive marker for venous thromboembolism and mortality in patients treated for diffuse large B-cell lymphoma. Hematol Oncol. 2016;. https:\/\/doi.org\/10.1002\/hon.2321 .","journal-title":"Hematol Oncol"},{"issue":"1","key":"1065_CR45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.thromres.2011.09.022","volume":"130","author":"K Yokoyama","year":"2012","unstructured":"Yokoyama K, Murata M, Ikeda Y, Okamoto S. Incidence and risk factors for developing venous thromboembolism in Japanese with diffuse large b-cell lymphoma. Thromb Res. 2012;130(1):7\u201311. https:\/\/doi.org\/10.1016\/j.thromres.2011.09.022 .","journal-title":"Thromb Res"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-017-1065-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-017-1065-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-017-1065-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T17:38:30Z","timestamp":1603474710000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-017-1065-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,4]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["1065"],"URL":"https:\/\/doi.org\/10.1007\/s12032-017-1065-4","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,4]]},"article-number":"5"}}